ATE364396T1 - Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern - Google Patents

Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern

Info

Publication number
ATE364396T1
ATE364396T1 AT01911971T AT01911971T ATE364396T1 AT E364396 T1 ATE364396 T1 AT E364396T1 AT 01911971 T AT01911971 T AT 01911971T AT 01911971 T AT01911971 T AT 01911971T AT E364396 T1 ATE364396 T1 AT E364396T1
Authority
AT
Austria
Prior art keywords
treatment
polyenes
fungal infection
synthesis inhibitors
beta glucan
Prior art date
Application number
AT01911971T
Other languages
English (en)
Inventor
James Peter Burnie
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Application granted granted Critical
Publication of ATE364396T1 publication Critical patent/ATE364396T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT01911971T 2000-04-06 2001-03-20 Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern ATE364396T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008305.5A GB0008305D0 (en) 2000-04-06 2000-04-06 Treatment of fungal infections

Publications (1)

Publication Number Publication Date
ATE364396T1 true ATE364396T1 (de) 2007-07-15

Family

ID=9889204

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01911971T ATE364396T1 (de) 2000-04-06 2001-03-20 Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern

Country Status (19)

Country Link
US (4) US20030180285A1 (de)
EP (4) EP1267925B8 (de)
JP (1) JP2003530357A (de)
CN (3) CN1420786A (de)
AT (1) ATE364396T1 (de)
AU (2) AU4089001A (de)
BR (1) BR0109846A (de)
CA (1) CA2401836A1 (de)
CY (1) CY1106794T1 (de)
DE (1) DE60128893T2 (de)
DK (1) DK1267925T3 (de)
ES (1) ES2287105T3 (de)
GB (1) GB0008305D0 (de)
NO (1) NO20024815L (de)
NZ (1) NZ520899A (de)
PL (1) PL358394A1 (de)
PT (1) PT1267925E (de)
RU (1) RU2262952C2 (de)
WO (1) WO2001076627A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050129665A1 (en) * 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US7651689B2 (en) * 2002-11-15 2010-01-26 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of infections
EP1457499A1 (de) * 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitoren des extrazellulären Hitzeschockproteins Hsp90
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
GB0409077D0 (en) 2004-04-23 2004-05-26 Neutec Pharma Plc Treatment of fungal infections
CA2572318A1 (en) * 2004-07-02 2006-01-12 Neutec Pharma Plc Treatment of cancer
SG153877A1 (en) * 2004-07-02 2009-07-29 Neutec Pharma Plc Treatment of cancer
EP1858542A4 (de) * 2005-02-24 2009-08-19 Joslin Diabetes Center Inc Zusammensetzungen und verfahren zur behandlung von gefässpermeabilität
JP5154406B2 (ja) * 2005-04-13 2013-02-27 アステックス、セラピューティックス、リミテッド 医薬化合物
GB0600168D0 (en) * 2006-01-05 2006-02-15 Neutec Pharma Plc A therapeutic composition
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
US20100113355A1 (en) * 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2008132174A1 (en) * 2007-04-27 2008-11-06 Novartis Ag An immunoglobulin composition
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
CN111116743B (zh) * 2018-10-30 2022-01-28 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
CN111679069A (zh) * 2019-12-31 2020-09-18 安徽中医药大学 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8915019D0 (en) * 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
GB2270076A (en) * 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
US6375955B1 (en) * 1995-09-22 2002-04-23 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6365165B1 (en) * 1995-09-22 2002-04-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US5834592A (en) * 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Also Published As

Publication number Publication date
BR0109846A (pt) 2003-06-03
US20100285029A1 (en) 2010-11-11
NZ520899A (en) 2005-03-24
RU2002129510A (ru) 2004-03-27
NO20024815L (no) 2002-12-02
CA2401836A1 (en) 2001-10-18
PL358394A1 (en) 2004-08-09
DE60128893T2 (de) 2007-12-06
US20030180285A1 (en) 2003-09-25
EP1267925A1 (de) 2003-01-02
EP1818062A1 (de) 2007-08-15
WO2001076627A8 (en) 2001-11-15
NO20024815D0 (no) 2002-10-04
PT1267925E (pt) 2007-09-04
CN101095952A (zh) 2008-01-02
AU2001240890B2 (en) 2005-06-16
DK1267925T3 (da) 2007-10-15
ES2287105T3 (es) 2007-12-16
EP1852128A1 (de) 2007-11-07
EP2011512A1 (de) 2009-01-07
US20080193459A1 (en) 2008-08-14
CN101683525A (zh) 2010-03-31
EP1267925B8 (de) 2007-08-29
CY1106794T1 (el) 2012-05-23
EP1818062A3 (de) 2007-10-24
RU2262952C2 (ru) 2005-10-27
AU4089001A (en) 2001-10-23
JP2003530357A (ja) 2003-10-14
GB0008305D0 (en) 2000-05-24
EP1267925B1 (de) 2007-06-13
CN1420786A (zh) 2003-05-28
DE60128893D1 (de) 2007-07-26
WO2001076627A1 (en) 2001-10-18
US20080181884A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
ATE364396T1 (de) Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
PT1639011E (pt) Anticorpos (dab) de domínio único peguilados
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
ATE279442T1 (de) Humanisierte antikörper, die amyloid beta peptid sequestrieren
MX421450B (es) Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19)
CY1118053T1 (el) Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea
NO20030621D0 (no) Anti-dual integrin antistoffer, sammensetninger, fremgangsmåter og anvendelser
BRPI0415230A (pt) anticorpo biespecìfico de substituição de proteìnas funcionais
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
EA200600275A1 (ru) Цитотоксический конъюгат, специфичный по отношению к са6 антигену, и способы его применения
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
BRPI0406574A (pt) Conjugados de anticorpo - antraciclina
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE50015629D1 (de) Verwendung cd28 spezifischer monoklonaler antikörpsetzung zur behandlung von virusinfektionen
DK1713830T3 (da) Anti-epcam-immunglobuliner
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
DK1534750T3 (da) Terapeutisk brug af monoklonale antistoffer mod angiotensin-II type-1 receptoren
ATE411056T1 (de) Lymphombehandlung mit dem monoklonalen anti- tenascin-antikörper
ATE435032T1 (de) Impstoff gegen yersinia mit einem oder zwei monoklonaler antikörper, die für yersinia pestis f1-antigen und v-antigen spezifisch sind

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1267925

Country of ref document: EP